Restructure

Pharma

Astellas, Takeda, RA Capital—Fierce Pharma Asia

Astellas CEO lays out the firm's new five-year plan. Takeda beats BMS in a psoriasis trial. RA provides China capabilities to its portfolio. And more.

Angus Liu Jun 12, 2026 8:23am

Inside Astellas CEO's plan to counter Xtandi's patent cliff

Jun 11, 2026 6:00pm

Takeda, GLP-1 generics, Gilead—Fierce Pharma Asia

Mar 27, 2026 8:38am

Takeda targets $1.3B in savings with new efficiency drive

Mar 25, 2026 10:44am

Large pharma companies reduced head counts by over 22K in 2025

Mar 23, 2026 4:25pm

Sandoz to break its biosimilars business out from generics

Mar 10, 2026 4:01pm